MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

May 23, 2023

Study Completion Date

May 23, 2023

Conditions

Metastatic Pancreatic Cancer

Interventions

BIOLOGICAL

MesoPher

autologous monocyte-derived dendritic cells loaded with PheraLys (tumor cell lysate)

BIOLOGICAL

Mitazalimab

agonistic human monoclonal (IgG1) antibody targeting CD40

Trial Locations (1)

Erasmus MC, Rotterdam

All Listed Sponsors

lead

Joachim Aerts, MD PhD

OTHER

NCT05650918 - MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial) | Biotech Hunter | Biotech Hunter